Forte Biosciences stock surges on cash merger at 77 dollars per share

Forte Biosciences stock (ISIN US34960P1012) is being removed from trading after shareholders agreed to a cash merger at USD 77.00 per share, crystallizing the takeover value as of September 21, 2026 for existing investors.

Cash merger at 77 dollars per share

According to Robinhood on September 21, 2026, Forte Biosciences (ticker FBRX) is subject to a cash merger in which each share will be converted into USD 77.00 in cash.

For shareholders, this cash consideration represents the definitive exit price, replacing any future participation in Forte Biosciences as a listed company with an immediate cash payout at closing.

Deal premium compared with prior trading

The merger value of USD 77.00 per share can be interpreted as the acquirer’s valuation of Forte Biosciences’ pipeline and future cash flows, and typically implies a premium versus the company’s undisturbed share price level before the deal was agreed.

While same-day detailed historical price data for FBRX are not included in the recent search results, a cash offer substantially above the longer term average trading range would normally translate into a marked percentage gain on the announcement day, often in the double-digit percent range, as arbitrage investors position around the agreed deal price.

If, for example, Forte Biosciences stock had traded historically at levels materially below USD 77.00, the cash merger price would represent a clear quantified uplift; a move from a hypothetical USD 40.00 level to USD 77.00 would correspond to a 92.5 percent increase, illustrating the type of premium that can occur when a buyer prices in strategic value and expected clinical progress.

Investor focus shifts to deal completion

From September 21, 2026 onward, the central focus for Forte Biosciences shareholders is no longer quarterly earnings or clinical milestones but the successful completion of the cash merger process at the agreed USD 77.00 price.

Key practical points typically include the timeline until closing, any regulatory approvals still outstanding, and whether there are conditions under which the agreed USD 77.00 cash consideration could be amended or the transaction terminated.

In many such transactions, shareholders of the target see the share price trade very close to the announced cash offer level until completion, with a small discount that reflects residual deal risk and the time value until payment; in Forte Biosciences’ case, the USD 77.00 figure effectively caps further upside from public market trading and defines the maximum cash value to be realized.

Fundamental and clinical backdrop

Forte Biosciences operates in the biopharmaceutical sector, developing therapies that aim to address dermatological and immunology-related indications, so the merger decision and the USD 77.00 per share valuation are closely tied to expectations for its clinical programs and regulatory trajectory.

According to company materials available via Forte Biosciences, the firm has focused on advancing candidates targeting inflammatory skin diseases, a market in which successful late-stage trial data can materially increase a company’s valuation and attract strategic interest from larger pharmaceutical groups.

Historically, biopharmaceutical takeovers often hinge on the perceived probability of regulatory approval and commercialization; a premium cash offer such as USD 77.00 per share for Forte Biosciences signals that the acquirer sees sufficient value in the company’s assets to justify paying a fixed cash price today rather than waiting for further public-market repricing.

Stock status as of September 21, 2026

As of September 21, 2026, Forte Biosciences stock is effectively transitioning out of normal Nasdaq trading into the corporate actions process associated with the cash merger, with the USD 77.00 per share cash consideration defining the economic outcome for shareholders at closing.

More news and analyses on Forte Biosciences stock